Today's Pre-Market Mover With Heavy Volume: Sanofi (SNY) - TheStreet

Trade-Ideas LLC identified

Sanofi

(

SNY

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Sanofi as such a stock due to the following factors:

  • SNY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $53.0 million.
  • SNY traded 109,345 shares today in the pre-market hours as of 9:12 AM, representing 10% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in SNY with the Ticky from Trade-Ideas. See the FREE profile for SNY NOW at Trade-Ideas

More details on SNY:

Sanofi researches, develops, and markets various therapeutic solutions. The stock currently has a dividend yield of 2.1%. SNY has a PE ratio of 27. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Sanofi has been 1.3 million shares per day over the past 30 days. Sanofi has a market cap of $132.9 billion and is part of the health care sector and drugs industry. Shares are up 10.8% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Sanofi as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:

  • SANOFI has improved earnings per share by 40.0% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. During the past fiscal year, SANOFI increased its bottom line by earning $2.01 versus $1.90 in the prior year. This year, the market expects an improvement in earnings ($3.19 versus $2.01).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 41.8% when compared to the same quarter one year prior, rising from $1,054.28 million to $1,494.50 million.
  • The gross profit margin for SANOFI is rather high; currently it is at 62.46%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 13.68% is above that of the industry average.
  • SNY's debt-to-equity ratio is very low at 0.26 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.77 is somewhat weak and could be cause for future problems.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.